Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
ACTU Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ACTU Stock 12 Month Forecast
Average Price Target
$10.67
▲(361.76% Upside)
| Highest Price Target$15.00 | Average Price Target$10.67 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$15
Buy
549.35%
Upside
Reiterated
05/18/26
Lucid Capital
$6→$5
Buy
116.45%
Upside
Reiterated
05/18/26
Craig-Hallum
$12
Buy
419.48%
Upside
Reiterated
05/12/26
B. Riley Securities
$20
Buy
765.80%
Upside
Initiated
08/26/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$15
Buy
549.35%
Upside
Reiterated
05/18/26
Lucid Capital
$6→$5
Buy
116.45%
Upside
Reiterated
05/18/26
Craig-Hallum
$12
Buy
419.48%
Upside
Reiterated
05/12/26
B. Riley Securities
$20
Buy
765.80%
Upside
Initiated
08/26/25
Best Analysts Covering Actuate Therapeutics, Inc.
3 Months
Success Rate
3/9 ratings generated profit
Average Return
-10.06%
Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -10.06% per trade.
1 Year
Success Rate
1/9 ratings generated profit
Average Return
-48.61%
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -48.61% per trade.
2 Years
Success Rate
1/9 ratings generated profit
Average Return
-49.20%
Copying Swayampakula Ramakanth's trades and holding each position for 2 Years would result in 11.11% of your transactions generating a profit, with an average return of -49.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ACTU Analyst Recommendation Trends
Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
4
2
2
2
6
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
2
2
2
6
Each month's total comprises the sum of three months' worth of ratings.
ACTU Financial Forecast
ACTU Stock Forecast FAQ
What is ACTU’s average 12-month price target, according to analysts?
Based on analyst ratings, Actuate Therapeutics, Inc.’s 12-month average price target is 10.67.
What is ACTU’s upside potential, based on the analysts’ average price target?
Actuate Therapeutics, Inc. has 361.76% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACTU a Buy, Sell or Hold?
Actuate Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Actuate Therapeutics, Inc.’s price target?
The average price target for Actuate Therapeutics, Inc. is 10.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $5.00. The average price target represents 361.76% Increase from the current price of $2.31.
The highest analyst price target is $15.00 ,the lowest forecast is $5.00. The average price target represents 361.76% Increase from the current price of $2.31.
What do analysts say about Actuate Therapeutics, Inc.?
Actuate Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of ACTU?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.